Recall Register

Drug recall: 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial…

Class I FDA enforcement event 93124. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Presence of Particulate Matter: identified as glass.

Class I, in the words of FDA

a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death

Pfizer Inc. started this drug recall on 2 Oct 2023. The firm address in the FDA record is in New York, NY. FDA put the recall in Class I. FDA event 93124 has 3 product records. The first FDA enforcement report date is 15 Nov 2023. The record gives the status Terminated, with the termination date 14 Feb 2025. 44 of the 281 drug events that started in 2023 have more product records. The median drug event of 2023 has 1 product record. The openFDA file has 281 drug events that started in 2023 and 325 that started in 2022.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.

Recalling firm

Pfizer Inc., New York, NY.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

3 product records in the event.

FDA event 93124: product records
Recall numberProductQuantityClassStatusReport date
D-0100-20244.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-5534-2424,900 vialsClass ITerminated15 Nov 2023
D-0101-20241% Lidocaine HCl Injection, USP, 50mg/5mL(10mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4904-1121,390 vialsClass ITerminated15 Nov 2023
D-0102-20242% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-113,200 vialsClass ITerminated15 Nov 2023

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class I: The highest of the three FDA recall classes.

The event in context

Drug events that started in 2023
281
Share of these events in Class I
15%
Product records in this event
3Median of the firm: 1
Events of the firm on the register
72

Other events of the firm

Other FDA enforcement events of Pfizer Inc.
InitiatedProduct (first record)TypeClassRecords
4 Aug 2025Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 600DrugClass II2
10 Jul 2025Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only, Distributed bDrugClass II2
28 May 2025DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, FDrugClass II1
20 May 2024Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit with Luer LockDrugClass II2
21 Dec 20234.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous UseDrugClass I3
8 Mar 2023MEKTOVI (binimetinib) tablets, 15 mg, 180-count bottle, Rx only, Distributed by: Array BioPharma Inc., a wholly owned suDrugClass III1
29 Dec 2022Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) CaseDrugClass II1
22 Dec 2022Vancomycin Hydrochloride for Injection, USP, 1.5 g/vial, Sterile powder, Single-dose Fliptop Vial, 10 vials per carton, DrugClass I1
27 Sep 2022Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc. LaDrugClass II1
22 Aug 2022PROPOFOL Injectable Emulsion, 1 g/100 mL (10 mg/mL), packaged in 100 mL glass fliptop vial (NDC 0409-4699-54) further paDrugClass I1

Pfizer Inc.: all 72 events

Official channels

Cite this page

Recall Register. FDA enforcement event 93124. https://recallregister.com/fda/i/93124/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
10 Nov 2026
Newest FDA report date on the register
4 Nov 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
What quantity of product is in FDA event 93124?
The event has 3 product records. The first record gives this quantity: 24,900 vials
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2023 have the same class?
15% of the 281 drug events that started in 2023 are in Class I.